Global Colorectal Cancer Drugs Market Research Report 2021

Publisher Name :
Date: 12-Mar-2021
No. of pages: 118
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment

- Vascular Endothelial Growth Factor (VEGF) Inhibitors

- Epidermal Growth Factor Receptor (EGFR) Inhibitors

- Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors

- BRAF or MEK Inhibitors

- Tyrosine Kinase (TKI) Inhibitors

- Immunomodulators

Segment

- Radiotherapy

- Chemotherapy

By Region

- North America

- - United States

- - Canada

- - Mexico

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- AB Science

- Amgen

- Array BioPharma

- Bayer

- Boehringer Ingelheim

- Bristol-Myers Squibb

- Elli Lilly

- Roch

- Hutchison MediPharma

- Merck & Co., Inc.

- Mologen

- Regeneron

- Sanofi

- Sumitomo Dainippon

- Taiho Pharmaceutical

- Vaccinogen

Global Colorectal Cancer Drugs Market Research Report 2021

Table of Contents
1 Colorectal Cancer Drugs Market Overview
1.1 Product Overview and Scope of Colorectal Cancer Drugs
1.2 Colorectal Cancer Drugs Segment
1.2.1 Global Colorectal Cancer Drugs Sales Growth Rate Comparison (2021-2027)
1.2.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors
1.2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitors
1.2.4 Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
1.2.5 BRAF or MEK Inhibitors
1.2.6 Tyrosine Kinase (TKI) Inhibitors
1.2.7 Immunomodulators
1.3 Colorectal Cancer Drugs Segment
1.3.1 Colorectal Cancer Drugs Sales Comparison : (2021-2027)
1.3.2 Radiotherapy
1.3.3 Chemotherapy
1.4 Global Colorectal Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Colorectal Cancer Drugs Revenue 2016-2027
1.4.2 Global Colorectal Cancer Drugs Sales 2016-2027
1.4.3 Colorectal Cancer Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Colorectal Cancer Drugs Market Competition by Manufacturers
2.1 Global Colorectal Cancer Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Colorectal Cancer Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Colorectal Cancer Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Colorectal Cancer Drugs Manufacturing Sites, Area Served, Product Type
2.5 Colorectal Cancer Drugs Market Competitive Situation and Trends
2.5.1 Colorectal Cancer Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Colorectal Cancer Drugs Players Market Share by Revenue
2.5.3 Global Colorectal Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Colorectal Cancer Drugs Retrospective Market Scenario by Region
3.1 Global Colorectal Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Colorectal Cancer Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Colorectal Cancer Drugs Market Facts & Figures by Country
3.3.1 North America Colorectal Cancer Drugs Sales by Country
3.3.2 North America Colorectal Cancer Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.3.3 Mexico
3.4 Europe Colorectal Cancer Drugs Market Facts & Figures by Country
3.4.1 Europe Colorectal Cancer Drugs Sales by Country
3.4.2 Europe Colorectal Cancer Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Colorectal Cancer Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Colorectal Cancer Drugs Sales by Region
3.5.2 Asia Pacific Colorectal Cancer Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Colorectal Cancer Drugs Market Facts & Figures by Country
3.6.1 Latin America Colorectal Cancer Drugs Sales by Country
3.6.2 Latin America Colorectal Cancer Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Colorectal Cancer Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Colorectal Cancer Drugs Sales by Country
3.7.2 Middle East and Africa Colorectal Cancer Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Colorectal Cancer Drugs Historic Market Analysis
4.1 Global Colorectal Cancer Drugs Sales Market Share (2016-2021)
4.2 Global Colorectal Cancer Drugs Revenue Market Share (2016-2021)
4.3 Global Colorectal Cancer Drugs Price (2016-2021)
5 Global Colorectal Cancer Drugs Historic Market Analysis
5.1 Global Colorectal Cancer Drugs Sales Market Share (2016-2021)
5.2 Global Colorectal Cancer Drugs Revenue Market Share (2016-2021)
5.3 Global Colorectal Cancer Drugs Price (2016-2021)
6 Key Companies Profiled
6.1 AB Science
6.1.1 AB Science Corporation Information
6.1.2 AB Science Description and Business Overview
6.1.3 AB Science Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 AB Science Product Portfolio
6.1.5 AB Science Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Array BioPharma
6.3.1 Array BioPharma Corporation Information
6.3.2 Array BioPharma Description and Business Overview
6.3.3 Array BioPharma Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Array BioPharma Product Portfolio
6.3.5 Array BioPharma Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bayer Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Boehringer Ingelheim Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Bristol-Myers Squibb Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Elli Lilly
6.6.1 Elli Lilly Corporation Information
6.6.2 Elli Lilly Description and Business Overview
6.6.3 Elli Lilly Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Elli Lilly Product Portfolio
6.7.5 Elli Lilly Recent Developments/Updates
6.8 Roch
6.8.1 Roch Corporation Information
6.8.2 Roch Description and Business Overview
6.8.3 Roch Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Roch Product Portfolio
6.8.5 Roch Recent Developments/Updates
6.9 Hutchison MediPharma
6.9.1 Hutchison MediPharma Corporation Information
6.9.2 Hutchison MediPharma Description and Business Overview
6.9.3 Hutchison MediPharma Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Hutchison MediPharma Product Portfolio
6.9.5 Hutchison MediPharma Recent Developments/Updates
6.10 Merck & Co., Inc.
6.10.1 Merck & Co., Inc. Corporation Information
6.10.2 Merck & Co., Inc. Description and Business Overview
6.10.3 Merck & Co., Inc. Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck & Co., Inc. Product Portfolio
6.10.5 Merck & Co., Inc. Recent Developments/Updates
6.11 Mologen
6.11.1 Mologen Corporation Information
6.11.2 Mologen Colorectal Cancer Drugs Description and Business Overview
6.11.3 Mologen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Mologen Product Portfolio
6.11.5 Mologen Recent Developments/Updates
6.12 Regeneron
6.12.1 Regeneron Corporation Information
6.12.2 Regeneron Colorectal Cancer Drugs Description and Business Overview
6.12.3 Regeneron Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Regeneron Product Portfolio
6.12.5 Regeneron Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Corporation Information
6.13.2 Sanofi Colorectal Cancer Drugs Description and Business Overview
6.13.3 Sanofi Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Sanofi Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 Sumitomo Dainippon
6.14.1 Sumitomo Dainippon Corporation Information
6.14.2 Sumitomo Dainippon Colorectal Cancer Drugs Description and Business Overview
6.14.3 Sumitomo Dainippon Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Sumitomo Dainippon Product Portfolio
6.14.5 Sumitomo Dainippon Recent Developments/Updates
6.15 Taiho Pharmaceutical
6.15.1 Taiho Pharmaceutical Corporation Information
6.15.2 Taiho Pharmaceutical Colorectal Cancer Drugs Description and Business Overview
6.15.3 Taiho Pharmaceutical Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Taiho Pharmaceutical Product Portfolio
6.15.5 Taiho Pharmaceutical Recent Developments/Updates
6.16 Vaccinogen
6.16.1 Vaccinogen Corporation Information
6.16.2 Vaccinogen Colorectal Cancer Drugs Description and Business Overview
6.16.3 Vaccinogen Colorectal Cancer Drugs Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Vaccinogen Product Portfolio
6.16.5 Vaccinogen Recent Developments/Updates
7 Colorectal Cancer Drugs Manufacturing Cost Analysis
7.1 Colorectal Cancer Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Colorectal Cancer Drugs
7.4 Colorectal Cancer Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Colorectal Cancer Drugs Distributors List
8.3 Colorectal Cancer Drugs Customers
9 Colorectal Cancer Drugs Market Dynamics
9.1 Colorectal Cancer Drugs Industry Trends
9.2 Colorectal Cancer Drugs Growth Drivers
9.3 Colorectal Cancer Drugs Market Challenges
9.4 Colorectal Cancer Drugs Market Restraints
10 Global Market Forecast
10.1 Colorectal Cancer Drugs Market Estimates and Projections
10.1.1 Global Forecasted Sales of Colorectal Cancer Drugs (2022-2027)
10.1.2 Global Forecasted Revenue of Colorectal Cancer Drugs (2022-2027)
10.2 Colorectal Cancer Drugs Market Estimates and Projections
10.2.1 Global Forecasted Sales of Colorectal Cancer Drugs (2022-2027)
10.2.2 Global Forecasted Revenue of Colorectal Cancer Drugs (2022-2027)
10.3 Colorectal Cancer Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Colorectal Cancer Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Colorectal Cancer Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Colorectal Cancer Drugs Sales (MT) Growth Rate Comparison (2021-2027)
Table 2. Global Colorectal Cancer Drugs Sales (MT) Comparison (2021-2027)
Table 3. Global Colorectal Cancer Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Colorectal Cancer Drugs Covered in This Study
Table 5. Global Colorectal Cancer Drugs Sales (MT) of Key Manufacturers (2016-2021)
Table 6. Global Colorectal Cancer Drugs Sales Share by Manufacturers (2016-2021)
Table 7. Global Colorectal Cancer Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Colorectal Cancer Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Colorectal Cancer Drugs Average Price (USD/Kg) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Colorectal Cancer Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Colorectal Cancer Drugs Product Type
Table 12. Global Colorectal Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Colorectal Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Colorectal Cancer Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Colorectal Cancer Drugs Sales by Region (2016-2021) & (MT)
Table 16. Global Colorectal Cancer Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Colorectal Cancer Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Colorectal Cancer Drugs Sales by Country (2016-2021) & (MT)
Table 19. North America Colorectal Cancer Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Colorectal Cancer Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Colorectal Cancer Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Colorectal Cancer Drugs Sales by Country (2016-2021) & (MT)
Table 23. Europe Colorectal Cancer Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Colorectal Cancer Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Colorectal Cancer Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Colorectal Cancer Drugs Sales by Region (2016-2021) & (MT)
Table 27. Asia Pacific Colorectal Cancer Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Colorectal Cancer Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Colorectal Cancer Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Colorectal Cancer Drugs Sales by Country (2016-2021) & (MT)
Table 31. Latin America Colorectal Cancer Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Colorectal Cancer Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Colorectal Cancer Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Colorectal Cancer Drugs Sales by Country (2016-2021) & (MT)
Table 35. Middle East and Africa Colorectal Cancer Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Colorectal Cancer Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Colorectal Cancer Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Colorectal Cancer Drugs Sales (MT) (2016-2021)
Table 39. Global Colorectal Cancer Drugs Sales Market Share (2016-2021)
Table 40. Global Colorectal Cancer Drugs Revenue (Million US$) (2016-2021)
Table 41. Global Colorectal Cancer Drugs Revenue Share (2016-2021)
Table 42. Global Colorectal Cancer Drugs Price (USD/Kg) (2016-2021)
Table 43. Global Colorectal Cancer Drugs Sales (MT) (2016-2021)
Table 44. Global Colorectal Cancer Drugs Sales Market Share (2016-2021)
Table 45. Global Colorectal Cancer Drugs Revenue (Million US$) (2016-2021)
Table 46. Global Colorectal Cancer Drugs Revenue Share (2016-2021)
Table 47. Global Colorectal Cancer Drugs Price (USD/Kg) (2016-2021)
Table 48. AB Science Corporation Information
Table 49. AB Science Description and Business Overview
Table 50. AB Science Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 51. AB Science Colorectal Cancer Drugs Product
Table 52. AB Science Recent Developments/Updates
Table 53. Amgen Corporation Information
Table 54. Amgen Description and Business Overview
Table 55. Amgen Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 56. Amgen Colorectal Cancer Drugs Product
Table 57. Amgen Recent Developments/Updates
Table 58. Array BioPharma Corporation Information
Table 59. Array BioPharma Description and Business Overview
Table 60. Array BioPharma Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 61. Array BioPharma Colorectal Cancer Drugs Product
Table 62. Array BioPharma Recent Developments/Updates
Table 63. Bayer Corporation Information
Table 64. Bayer Description and Business Overview
Table 65. Bayer Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 66. Bayer Colorectal Cancer Drugs Product
Table 67. Bayer Recent Developments/Updates
Table 68. Boehringer Ingelheim Corporation Information
Table 69. Boehringer Ingelheim Description and Business Overview
Table 70. Boehringer Ingelheim Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 71. Boehringer Ingelheim Colorectal Cancer Drugs Product
Table 72. Boehringer Ingelheim Recent Developments/Updates
Table 73. Bristol-Myers Squibb Corporation Information
Table 74. Bristol-Myers Squibb Description and Business Overview
Table 75. Bristol-Myers Squibb Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 76. Bristol-Myers Squibb Colorectal Cancer Drugs Product
Table 77. Bristol-Myers Squibb Recent Developments/Updates
Table 78. Elli Lilly Corporation Information
Table 79. Elli Lilly Description and Business Overview
Table 80. Elli Lilly Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 81. Elli Lilly Colorectal Cancer Drugs Product
Table 82. Elli Lilly Recent Developments/Updates
Table 83. Roch Corporation Information
Table 84. Roch Description and Business Overview
Table 85. Roch Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 86. Roch Colorectal Cancer Drugs Product
Table 87. Roch Recent Developments/Updates
Table 88. Hutchison MediPharma Corporation Information
Table 89. Hutchison MediPharma Description and Business Overview
Table 90. Hutchison MediPharma Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 91. Hutchison MediPharma Colorectal Cancer Drugs Product
Table 92. Hutchison MediPharma Recent Developments/Updates
Table 93. Merck & Co., Inc. Corporation Information
Table 94. Merck & Co., Inc. Description and Business Overview
Table 95. Merck & Co., Inc. Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 96. Merck & Co., Inc. Colorectal Cancer Drugs Product
Table 97. Merck & Co., Inc. Recent Developments/Updates
Table 98. Mologen Corporation Information
Table 99. Mologen Description and Business Overview
Table 100. Mologen Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 101. Mologen Colorectal Cancer Drugs Product
Table 102. Mologen Recent Developments/Updates
Table 103. Regeneron Corporation Information
Table 104. Regeneron Description and Business Overview
Table 105. Regeneron Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 106. Regeneron Colorectal Cancer Drugs Product
Table 107. Regeneron Recent Developments/Updates
Table 108. Sanofi Corporation Information
Table 109. Sanofi Description and Business Overview
Table 110. Sanofi Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 111. Sanofi Colorectal Cancer Drugs Product
Table 112. Sanofi Recent Developments/Updates
Table 113. Sumitomo Dainippon Corporation Information
Table 114. Sumitomo Dainippon Description and Business Overview
Table 115. Sumitomo Dainippon Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 116. Sumitomo Dainippon Colorectal Cancer Drugs Product
Table 117. Sumitomo Dainippon Recent Developments/Updates
Table 118. Taiho Pharmaceutical Corporation Information
Table 119. Taiho Pharmaceutical Description and Business Overview
Table 120. Taiho Pharmaceutical Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 121. Taiho Pharmaceutical Colorectal Cancer Drugs Product
Table 122. Taiho Pharmaceutical Recent Developments/Updates
Table 123. Vaccinogen Corporation Information
Table 124. Vaccinogen Description and Business Overview
Table 125. Vaccinogen Colorectal Cancer Drugs Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2021)
Table 126. Vaccinogen Colorectal Cancer Drugs Product
Table 127. Vaccinogen Recent Developments/Updates
Table 128. Production Base and Market Concentration Rate of Raw Material
Table 129. Key Suppliers of Raw Materials
Table 130. Colorectal Cancer Drugs Distributors List
Table 131. Colorectal Cancer Drugs Customers List
Table 132. Colorectal Cancer Drugs Market Trends
Table 133. Colorectal Cancer Drugs Growth Drivers
Table 134. Colorectal Cancer Drugs Market Restraints
Table 135. Global Colorectal Cancer Drugs Sales Forecast (2022-2027) & (MT)
Table 136. Global Colorectal Cancer Drugs Sales Market Share Forecast (2022-2027)
Table 137. Global Colorectal Cancer Drugs Revenue Forecast (2022-2027) & (US$ Million)
Table 138. Global Colorectal Cancer Drugs Revenue Market Share Forecast (2022-2027)
Table 139. Global Colorectal Cancer Drugs Sales Forecast (2022-2027) & (MT)
Table 140. Global Colorectal Cancer Drugs Sales Market Share Forecast (2022-2027)
Table 141. Global Colorectal Cancer Drugs Revenue Forecast (2022-2027) & (US$ Million)
Table 142. Global Colorectal Cancer Drugs Revenue Market Share Forecast (2022-2027)
Table 143. Global Colorectal Cancer Drugs Sales Forecast by Region (2022-2027) & (MT)
Table 144. Global Colorectal Cancer Drugs Sales Market Share Forecast by Region (2022-2027)
Table 145. Global Colorectal Cancer Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 146. Global Colorectal Cancer Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Colorectal Cancer Drugs
Figure 2. Global Colorectal Cancer Drugs Market Share in 2020 & 2027
Figure 3. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Picture
Figure 4. Epidermal Growth Factor Receptor (EGFR) Inhibitors Product Picture
Figure 5. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors Product Picture
Figure 6. BRAF or MEK Inhibitors Product Picture
Figure 7. Tyrosine Kinase (TKI) Inhibitors Product Picture
Figure 8. Immunomodulators Product Picture
Figure 9. Global Colorectal Cancer Drugs Market Share in 2020 & 2027
Figure 10. Radiotherapy
Figure 11. Chemotherapy
Figure 12. Global Colorectal Cancer Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Colorectal Cancer Drugs Market Size 2016-2027 (US$ Million)
Figure 14. Global Colorectal Cancer Drugs Sales 2016-2027 (MT)
Figure 15. Global Colorectal Cancer Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. Colorectal Cancer Drugs Sales Share by Manufacturers in 2020
Figure 17. Global Colorectal Cancer Drugs Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Colorectal Cancer Drugs Players: Market Share by Revenue in 2020
Figure 19. Colorectal Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Colorectal Cancer Drugs Sales Market Share by Region (2016-2021)
Figure 21. Global Colorectal Cancer Drugs Sales Market Share by Region in 2020
Figure 22. Global Colorectal Cancer Drugs Revenue Market Share by Region (2016-2021)
Figure 23. Global Colorectal Cancer Drugs Revenue Market Share by Region in 2020
Figure 24. United States Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Mexico Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Germany Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. France Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. U.K. Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Italy Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Russia Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. China Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Japan Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. South Korea Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. India Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Australia Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Taiwan Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Indonesia Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Thailand Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Malaysia Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Philippines Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Vietnam Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Mexico Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Brazil Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Argentina Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Turkey Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Saudi Arabia Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. U.A.E Colorectal Cancer Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Sales Market Share of Colorectal Cancer Drugs (2016-2021)
Figure 50. Sales Market Share of Colorectal Cancer Drugs (2016-2021)
Figure 51. Sales Market Share of Colorectal Cancer Drugs in 2020
Figure 52. Revenue Share of Colorectal Cancer Drugs (2016-2021)
Figure 53. Revenue Share of Colorectal Cancer Drugs in 2020
Figure 54. Manufacturing Cost Structure of Colorectal Cancer Drugs
Figure 55. Manufacturing Process Analysis of Colorectal Cancer Drugs
Figure 56. Colorectal Cancer Drugs Industrial Chain Analysis
Figure 57. Channels of Distribution
Figure 58. Distributors Profiles
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
  • Global 5-Fluorouracil Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 76
    The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030. North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
  • Global Carboplatin Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
  • Global Neutropenia Drugs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 96
    The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
  • Global Small Molecule Cancer Drug Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
  • Global Capecitabine Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 80
    Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
  • Global Oxaliplatin Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104
    Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely. In this report, only The finished drug is covered, exclude API. The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
  • Global Cancer Treatment Drugs Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period. The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
  • Global Capecitabine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93
    According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period. The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
  • Global Methotrexate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95
    According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period. The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs